Skip to main content
. 2022 Oct 6;11(10):e39785. doi: 10.2196/39785

Table 3.

Schedule of assessments.

Assessment Screening Admission (day 1) On study (days 1-2) Discharge (day 2) Poststudy follow-upa
Participants are free to use NPb or smoke as usualc
Participants collect used NPsd



Unused pouch collection



Informed consent



Inclusion and exclusion criteria



Sociodemographic data



Medical history



Prior and concomitant medications
Tobacco and nicotine use history questionnaire



Pregnancy test (urine and serum)e


COVID-19 test (Sweden only)


Height, weight, BMI, and waist circumference



Vital signsf


12-lead ECGg



Physical examinationh

Urinary cotinine screen (dipstick)


Urine drugs of abuse panel and alcohol screeni


Serum biochemistry and hematology



Urinalysis



Virology (hepatitis B and C and HIV)



Exhaled carbon monoxide measurementj


Spirometry (without bronchodilator)k



FeNOl measurementm



24-hour urine collection



Blood sampling for biomarker analysisn



Carotid intima-media thickness assessment



Quality-of-life questionnaire



Oral health assessment



Adverse event recordingo

aWithin 7 days of discharge.

bNP: nicotine pouch.

cAt any time, unless it would interfere with study assessments.

dAll pouches used during confinement collected from participants in arm A commencing just before the start of 24-hour urine collection.

eUrine pregnancy test only at admission.

fIncludes pulse rate, systolic and diastolic blood pressure, respiratory rate, and tympanic temperature.

gECG: electrocardiogram.

hFull physical examination at screening; symptom-driven physical examination at admission and discharge, if deemed necessary.

iBy breath test (alcometer).

jNo food, smoking, or nicotine pouch use within 30 minutes before assessment.

kNo food within 2 hours before assessment; no smoking or nicotine pouch use within 1 hour before assessment.

lFeNO: fractional exhaled nitric oxide.

mNo food or drink within 1 hour before assessment; no smoking or nicotine pouch use within 30 minutes before assessment.

nBlood sampling for the following biomarker analysis: N-(2-cyanoethyl)valine, carboxyhemoglobin (drawn between 6 PM and 8 PM), lipid panel (for high-density lipoprotein analysis), soluble intercellular adhesion molecule-1, and white blood cell count.

oReporting begins at provision of informed consent.